PA8651401A1 - SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE - Google Patents

SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE

Info

Publication number
PA8651401A1
PA8651401A1 PA20058651401A PA8651401A PA8651401A1 PA 8651401 A1 PA8651401 A1 PA 8651401A1 PA 20058651401 A PA20058651401 A PA 20058651401A PA 8651401 A PA8651401 A PA 8651401A PA 8651401 A1 PA8651401 A1 PA 8651401A1
Authority
PA
Panama
Prior art keywords
dosage forms
solid oral
oral dosage
estradiol
forms containing
Prior art date
Application number
PA20058651401A
Other languages
Spanish (es)
Inventor
Adrian Funke
Torsten Wagner
Kristina Mueller
Christian Zurth
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PA8651401A1 publication Critical patent/PA8651401A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

FORMAS DE DOSIFICACION ORAL SOLIDAS QUE CONTIENEN UNA DOSIS MUY BAJA DE ESTRADIOL. LAS FORMAS DE DOSIFICACION SE FORMULAN DE MODO TAL QUE SE EVITA LA DEGRADACION DEL ESTRADIOL Y SE MINIMIZA EL CONTENIDO DE POLIVINILPIRROLIDONA, AL TIEMPO QUE AUN SE LOGRA UNA DISOLUCION RAPIDA SIMILAR DEL ESTRADIOL. LAS FORMAS DE DOSIFICACION SON UTILES PARA PREVENIR O TRATAR UNA CONDICION FISICA EN UNA MUJER, PROVOCADA POR NIVELES ENDRÓGENOS INSUFICIENTES DE ESTRADIOL.SOLID ORAL DOSAGE FORMS CONTAINING A VERY LOW DOSE OF ESTRADIOL. THE DOSAGE FORMS ARE FORMULATED AS IS TO PREVENT THE DEGRADATION OF ESTRADIOL AND MINIMIZE THE CONTENT OF POLYVINYL PIRROLIDONE, AT THE TIME THAT STILL A SIMILAR RAPID DISSOLUTION OF ESTRADIOL IS ACHIEVED. DOSAGE FORMS ARE USEFUL TO PREVENT OR TREAT A PHYSICAL CONDITION IN A WOMAN, CAUSED BY INSUFFICIENT LEVELS OF ESTRADIOL.

PA20058651401A 2004-11-02 2005-11-02 SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE PA8651401A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04078014 2004-11-02

Publications (1)

Publication Number Publication Date
PA8651401A1 true PA8651401A1 (en) 2006-12-07

Family

ID=34928627

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058651401A PA8651401A1 (en) 2004-11-02 2005-11-02 SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE

Country Status (21)

Country Link
EP (1) EP1814526A2 (en)
JP (1) JP2008518895A (en)
KR (1) KR20070085558A (en)
CN (1) CN101094656A (en)
AR (1) AR053650A1 (en)
AU (1) AU2005300658A1 (en)
BR (1) BRPI0517940A (en)
CA (1) CA2585095A1 (en)
CR (1) CR9112A (en)
CU (1) CU20070094A7 (en)
EA (1) EA013262B1 (en)
GT (1) GT200500315A (en)
IL (1) IL182635A0 (en)
MX (1) MX2007005281A (en)
NO (1) NO20072704L (en)
PA (1) PA8651401A1 (en)
PE (1) PE20061126A1 (en)
TW (1) TW200621312A (en)
UY (1) UY29185A1 (en)
WO (1) WO2006048261A2 (en)
ZA (1) ZA200705012B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
KR20080047959A (en) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 Naphthoquinone-based pharmaceutical composition for treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
DE102009007771B4 (en) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Buccal administration system containing 17α-estradiol
JP5820465B2 (en) * 2010-04-15 2015-11-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Very low dose solid oral dosage form for HRT
JP5852639B2 (en) 2010-04-15 2016-02-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Low dose solid oral dosage form for HRT
CN112516149B (en) * 2020-07-21 2023-07-18 南方医科大学 Application of estradiol benzoate or pharmaceutically acceptable salt thereof in preparation of anti-coronavirus drugs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125069C (en) * 1963-12-24
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
FR2739558B1 (en) * 1995-10-05 1997-11-28 Innothera Lab Sa UNITAL GALENIC FORM FOR LOCAL HORMONOTHERAPY OF VAGINAL DROUGHT
FR2754179B1 (en) * 1996-10-08 1998-12-24 Theramex NOVEL HORMONONAL COMPOSITION AND ITS USE
US6326366B1 (en) * 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
BR0115067A (en) * 2000-10-30 2004-04-06 Univ Zuerich Gnrh Analogs for Urinary Incontinence Treatment
PT1343508E (en) * 2000-12-15 2012-02-20 Novo Nordisk Femcare Ag Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis
FR2823976A1 (en) * 2001-04-25 2002-10-31 Theramex NOVEL HORMONAL COMPOSITION AND ITS USE
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
JP2004155779A (en) * 2002-10-16 2004-06-03 Taisho Pharmaceut Co Ltd Peroral composition for preventing and treating climacteric symptom

Also Published As

Publication number Publication date
CN101094656A (en) 2007-12-26
PE20061126A1 (en) 2006-11-11
GT200500315A (en) 2006-06-06
NO20072704L (en) 2007-05-29
EA200700979A1 (en) 2007-10-26
CU20070094A7 (en) 2009-09-08
EA013262B1 (en) 2010-04-30
JP2008518895A (en) 2008-06-05
ZA200705012B (en) 2008-10-29
WO2006048261A3 (en) 2006-09-21
UY29185A1 (en) 2006-05-31
CR9112A (en) 2007-11-23
IL182635A0 (en) 2007-07-24
AR053650A1 (en) 2007-05-16
WO2006048261A2 (en) 2006-05-11
BRPI0517940A (en) 2008-10-21
CA2585095A1 (en) 2006-05-11
EP1814526A2 (en) 2007-08-08
TW200621312A (en) 2006-07-01
MX2007005281A (en) 2008-03-11
KR20070085558A (en) 2007-08-27
AU2005300658A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
AR055095A1 (en) NEW MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
UY28862A1 (en) NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II
AR077573A2 (en) USE OF A TNF INHIBITOR AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
AR060836A1 (en) A TRANS-MUCOSA DISK TO ADMINISTER AN ACTIVE AGENT, A TRANS-MUCOSA COMPOSITION AND THE METHOD OF ADMINISTRATION OBTAINED
DOP2009000155A (en) DERIVATIVES OF FITTED HETERO-PENTACICLO-FENILO, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF A CONDITION MEDIATED BY P38
AR068185A1 (en) COMPOSITIONS OF LAMOTRIGIN ORAL DISINTEGRATION TABLETS
ECSP066959A (en) MACROCICLICAL COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
CL2011000916A1 (en) Use of a combination of an epoxy ketone peptide proteasome inhibitor or an acceptable pharmaceutical salt thereof, and one or more other therapeutic agents to treat cancer.
CL2013001136A1 (en) A phosphodiesterase 7 (pde7) inhibitory agent to be used in the treatment or reduction of the possibility of an addiction; and pharmaceutical composition, unit dosage form and pharmaceutical kit including phosphodiesterase 7 inhibitor (pde7) and an additional therapeutic agent.
NI200800169A (en) USE OF BENZO-FUSED HETEROCYCLIC SULFAMID DERIVATIVES FOR THE TREATMENT OF PAIN
PA8651401A1 (en) SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE
PE20070333A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AGOMELATIN FOR THE TREATMENT OF SLEEP DISORDERS IN DEPRESSED PATIENTS
CU20090112A6 (en) MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
ECSP066553A (en) MASTICABLE ADMINISTRATION FORMS, NOT INDIVIDUALLY DOSED COMPRESSED.
ECSP066805A (en) SILINAN COMPOUNDS AS INHIBITORS OF CYSTEINE PROTEASA
AR026254A1 (en) THE USE OF A CONTROLLED RELEASE PREPARATION FOR THE PREPARATION OF A MEDICINAL PRODUCT TO INCREASE THE DOSE OR SYSTEM EXPOSURE OF A PHARMACO THAT INHIBITS PHOSPHODESTERASE 4
ECSP10010464A (en) USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
PE20130147A1 (en) PHARMACEUTICAL COMBINATION OF THEOBROMINE AND A NON-OPIOID ANTITUSSIVE AGENT
CL2004000984A1 (en) ORAL DOSAGE FORM OF A MAGNESIUM SALT OF (S) -PANTOPAZOL, FOR THE PROPHYLAXIS OR TREATMENT OF A CONDITION ASSOCIATED TO INHIBIT THE PROTONIC PUMP.
CL2004000767A1 (en) ORAL DOSING UNIT INCLUDING AN ANTAGONIST AGENT FOR PUMPS OF PROTONS AND EXCIPIENTS OF BASIC CHARACTER; PROCEDURE FOR PREPARATION, USEFUL TO TREAT DISEASES CAUSED BY AN INCREASED SECRETION OF GASTRIC ACIDS.
AR061046A1 (en) MIRTAZAPINE FOR THE TREATMENT OF NEUROPATHIC PAIN
NI201000185A (en) METHODS FOR USING CORTICOTROPIN RELEASING FACTOR FOR THE TREATMENT OF CANCER.
AR048355A1 (en) ASSOCIATION BETWEEN A HETEROCICLICAL COMPOUND AND AN ANTIOXIDANT AGENT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR057161A1 (en) METHODS AND DOSAGE FORMS OF BENZISOXAZOL DERIVATIVES WITH BETTER EFFECTIVENESS